Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta‐analysis of risk factors
Background Wide variations in revision endoscopic sinus surgery (ESS) rates for chronic rhinosinusitis with nasal polyposis (CRSwNP) have been reported. It is important to understand expected revision rates and factors that impact the need for revision. Methods A literature search was conducted on P...
Saved in:
Published in | International forum of allergy & rhinology Vol. 10; no. 2; pp. 199 - 207 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.02.2020
|
Subjects | |
Online Access | Get full text |
ISSN | 2042-6976 2042-6984 2042-6984 |
DOI | 10.1002/alr.22487 |
Cover
Summary: | Background
Wide variations in revision endoscopic sinus surgery (ESS) rates for chronic rhinosinusitis with nasal polyposis (CRSwNP) have been reported. It is important to understand expected revision rates and factors that impact the need for revision.
Methods
A literature search was conducted on PubMed, Scopus, and the Cochrane Database of Systematic Reviews. Following PRISMA guidelines, a systematic review and meta‐analysis was performed on studies that reported revision surgery data for CRSwNP patients.
Results
Forty‐five studies with 34,220 subjects were meta‐analyzed, with an overall revision rate of 18.6% (95% confidence interval, 14.1%‐23.6%). Studies with extractable follow‐up data reported a mean revision rate of 16.2% over a weighted mean follow‐up of 89.6 months. Factors associated with increased revision rates included allergic fungal rhinosinusitis (28.7%), aspirin‐exacerbated respiratory disease (27.2%), asthma (22.6%), prior polypectomy (26.0%), and publication prior to 2008 (22.7%) (p < 0.05 for all).
Conclusion
Although polyps can recur after ESS, reported long‐term ESS revision rates are approximately 14% to 24%. Identifying risk factors for revision surgery can help manage patient expectations and determine optimal personalized treatments. |
---|---|
Bibliography: | Presented orally at the Annual Meeting of the American Rhinologic Society, on September 13‐14, 2019, in New Orleans, LA. Potential conflict of interest: Z.M.S.: Olympus, Optinose, Novartis, Regeneron, and Healthy Humming (not affiliated with this study), consultant; R.J.S.: Olympus, Arrinex, Optinose, Sanofi, and Healthy Humming (not affiliated with this study), consultant. ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 2042-6976 2042-6984 2042-6984 |
DOI: | 10.1002/alr.22487 |